Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CCR6 | P51684 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20188230 | 0.89 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 | |
| SCHEMBL19844603 | 0.85 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 | |
| SCHEMBL18154113 | 0.85 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 | |
| SCHEMBL29144367 | 0.84 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1KMT2ATDP1MAPK1 | |
| SCHEMBL392835 | 0.82 | PAM (0.50) | ALDH1A1SMN1; SMN2L3MBTL1KMT2AMAPK1 | |
| SCHEMBL7855035 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 | |
| SCHEMBL30327111 | 0.82 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 | |
| Glycolic Acid SCHEMBL537258 | 0.81 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 | |
| SCHEMBL393742 | 0.81 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 | |
| SCHEMBL393395 | 0.81 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2L3MBTL1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-09 | — | — | US | disclosed |
| US-8618152-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8486989-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-16 | — | — | US | disclosed |
| WO-1996028465-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| WO-1996028464-A1 | BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0666842-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1995006061-A1 | RETROVIRAL PROTEASE INHIBITORS AND COMBINATIONS THEREOF | G.D. SEARLE & CO. (US) | 1995-03-02 | — | — | WO | disclosed |
| WO-1994010134-A1 | HYDROXYETHYLAMINO SULFAMIC ACID DERIVATIVES USEFUL AS RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-4375433-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1983-03-01 | — | — | US | disclosed |
| US-4252722-A | CHEMICAL INTERMEDIATE | MERCK & CO., INC. (US) | 1981-02-24 | — | — | US | disclosed |
| US-4250085-A | PHOSPHONATE-CONTAINING OLIGOPEPTIDES, BACTERICIDES | HOFFMANN-LA ROCHE INC. (US) | 1981-02-10 | — | — | US | disclosed |
| EP-0010312-A2 | Process for the preparation of 6-hydroxymethyl-2-(beta-aminoethylthio)-1-carbadethiapen-2-em-3-carboxylic acid and intermediates useful in this process | MERCK & CO. INC. (US) | 1980-04-30 | — | — | EP | disclosed |
| EP-0002822-A1 | Phosphorus containing peptide derivatives, their production, intermediates for their production and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | ALDH1A1 5/4885SMN1; SMN2 96/4885L3MBTL1 449/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | ALDH1A1 5/4885SMN1; SMN2 96/4885L3MBTL1 449/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | ALDH1A1 9/4885SMN1; SMN2 92/4885L3MBTL1 743/4885 |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | APEH, CYP2C9, ALDH1A2 | ALDH1A1 8/4885SMN1; SMN2 117/4885L3MBTL1 831/4885 |
| US-20140010784-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | ALDH1A1 2742/4885SMN1; SMN2 2528/4885L3MBTL1 1032/4885 |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | ALDH1A1 5/4885SMN1; SMN2 96/4885L3MBTL1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.